# Onvuzosiran PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/onvuzosiran

> The next catalyst for onvuzosiran, sponsored by ADARx Pharmaceuticals, Inc. (ADRX), is its topline data readout, late 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | onvuzosiran |
| Codes |  |
| Sponsor | ADARx Pharmaceuticals, Inc. (ADRX) https://sec-api.dev/companies/adrx/catalysts |
| Indications |  |
| Modality | sirna |
| FDA designations | fast track, orphan |

## Timeline

### Jan 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2026-09-04, last confirmed 2026-09-28.
- SEC prospectus (424B) (accession 0001193125-26-403094): "In January 2024, we initiated our Phase 2a clinical trial of SC doses of onvuzosiran in patients with HAE." https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm
- SEC registration statement (S-1) (accession 0001193125-26-383838): "In January 2024, we initiated our Phase 2a clinical trial of SC doses of onvuzosiran in patients with HAE." https://www.sec.gov/Archives/edgar/data/1802369/000119312526383838/d903461ds1.htm

### late 2027: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-09-04, last confirmed 2026-09-28.
- SEC prospectus (424B) (accession 0001193125-26-403094): "STOP-HAE enrollment is ongoing, with topline data expected by the end of 2027." https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm
- SEC prospectus (424B) (accession 0001193125-26-403094): "Enrollment is ongoing, with topline data expected by the end of 2027." https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm
- SEC registration statement (S-1) (accession 0001193125-26-383838): "STOP-HAE enrollment is ongoing, with topline data expected by the end of 2027." https://www.sec.gov/Archives/edgar/data/1802369/000119312526383838/d903461ds1.htm
- SEC registration statement (S-1) (accession 0001193125-26-383838): "Enrollment is ongoing, with topline data expected by the end of 2027." https://www.sec.gov/Archives/edgar/data/1802369/000119312526383838/d903461ds1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/onvuzosiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Onvuzosiran PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/onvuzosiran

```bibtex
@misc{secapidev_pdufa_onvuzosiran_20261116,
  title        = {Onvuzosiran PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/onvuzosiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_onvuzosiran_20261116","title":"Onvuzosiran PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/onvuzosiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
